Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed/Refractory Hematological Malignancies

NCT05528887 is registered in ClinicalTrials.gov with The Affiliated People's Hospital of Ningbo University as lead sponsor.

NCT NCT05528887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05528887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed/Refractory Hematological Malignancies
Lead sponsor
The Affiliated People's Hospital of Ningbo University
Phase
Phase 1
Overall status
Unknown status
Start date
September 16, 2021
Completion date
June 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, myeloma, relapsed/refractory hematological malignancies